BerandaHELP • NASDAQ
add
Cybin Inc
Tutup sebelumnya
$7,61
Rentang hari
$7,22 - $8,10
Rentang tahun
$5,76 - $8,97
Volume Rata-Rata
520,82 rb
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 33,24 jt | 31,95% |
Penghasilan bersih | -30,58 jt | -43,25% |
Margin laba bersih | — | — |
Penghasilan per saham | -1,46 | -92,11% |
EBITDA | -33,19 jt | -32,03% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 135,02 jt | -35,39% |
Total aset | 258,62 jt | -14,37% |
Total liabilitas | 21,42 jt | 112,14% |
Total ekuitas | 237,20 jt | — |
Saham yang beredar | 23,03 jt | — |
Harga terhadap nilai buku | 0,69 | — |
Tingkat pengembalian aset | -32,45% | — |
Tingkat pengembalian modal | -34,81% | — |
Arus Kas
Perubahan kas bersih
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -30,58 jt | -43,25% |
Kas dari operasi | -21,11 jt | -1,96% |
Kas dari investasi | -1,08 jt | -404,19% |
Kas dari pembiayaan | 20,98 jt | -89,01% |
Perubahan kas bersih | -1,27 jt | -100,75% |
Arus kas bebas | -11,14 jt | 12,30% |
Tentang
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Didirikan
2019
Kantor pusat
Situs
Karyawan
50
